CAPR vs KPTI
CAPR: Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for Duchenne muscular dystrophy treatment. KPTI: Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer.
Side-by-side fundamentals
| Metric | CAPR | KPTI | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $4.18 | $1.95 | |
| Market cap as of 2026-08-08 | $244M | $44M | |
| PEG as of 2026-08-08 | -0.03 | -0.01 | CAPR lower |
| Net margin as of 2026-08-08 | -181.7% | -129.0% | KPTI higher |
| Gross margin as of 2026-08-08 | n/a | +96.0% | |
| Operating margin as of 2026-08-08 | -191.1% | -97.0% | KPTI higher |
| ROE as of 2026-08-08 | -59.3% | -182.4% | CAPR higher |
| ROA as of 2026-08-08 | -48.6% | -176.9% | CAPR higher |
| Debt / equity as of 2026-08-08 | 0.02 | 3.78 | CAPR lower |
| Revenue growth (YoY) as of 2026-08-08 | n/a | +6.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.4% | |
| Beta as of 2026-08-08 | 0.27 | 0.97 | |
| 1-year return as of 2026-08-06 close | -46.0% | -51.6% | CAPR higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.